Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)

NCT04901325 is registered in ClinicalTrials.gov with Oregon Health and Science University as lead sponsor.

NCT NCT04901325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04901325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
Lead sponsor
Oregon Health and Science University
Phase
Phase 2
Overall status
Completed
Start date
October 3, 2023
Completion date
May 7, 2025
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pyoderma, pyoderma gangrenosum, skin diseases, skin ulcer, wound heal